|1.||Greiff, L: 1 article (05/2004)|
|2.||Ahlström-Emanuelsson, C: 1 article (05/2004)|
|3.||Andersson, M: 1 article (05/2004)|
|4.||Schrewelius, C: 1 article (05/2004)|
|5.||Persson, C: 1 article (05/2004)|
05/01/2004 - "Topical treatment with aqueous solutions of rofleponide palmitate attenuates nasal symptoms and improves nasal PIF in allergic rhinitis. "
05/01/2004 - "Rofleponide palmitate is an esterified glucocorticosteroid pro-drug with a promising pre-clinical profile designed to deliver topical airway treatment for allergic rhinitis and asthma in a novel manner. "
05/01/2004 - "To examine whether rofleponide palmitate affects nasal symptoms and peak inspiratory flow (PIF) in a pollen-season model of allergic rhinitis and to compare any such effects with those of another glucocorticosteroid (i.e., budesonide). "
05/01/2004 - "Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis."
|2.||Seasonal Allergic Rhinitis (Hay Fever)
05/01/2004 - "During the pollen-free season, 40 patients with strictly seasonal allergic rhinitis received topical nasal spray treatment with an aqueous solution of rofleponide palmitate 400 microg and an aqueous solution of budesonide 128 microg once daily for 10 days in a double-blind, placebo-controlled, and crossover study. "
|3.||Asthma (Bronchial Asthma)